Sun Pharmaceuticals Ltd.

is India's largest (by market capitalization) and the world's 5th largest

specialty generic pharmaceutical company. The company manufactures and sells high-quality,
affordable medicines in over 150 countries across 6 continents.

As of 31st March 2017, Sun Pharmaceuticals Ltd. had an intellectual capital of 2,000+ scientists, and
had invested over 7% of its annual revenues in R&D. The company has over 48
manufacturing facilities across the globe. 30 of their brands are among the top 300 pharma brands in
India.

Valuation (Rs. Cr)

Intellectual Capital (IC) 26,997.89

Net Worth (NW) 44,722.60

Intrinsic Worth (IW) 71,720.49

Market Cap (MC) 114,890.80

Economic Value Added -1,264.73

The company markets its pharmaceutical formulations as generics and branded generics in India and
all major international markets. The therapeutic segments covered by the company's portfolio of
2000+ molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology,
gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory,
oncology, dental and nutritionals.

Sun Pharma's business is broadly categorized into four segments: Active Pharmaceutical Ingredients
(API), International Branded Generics, Indian Branded Generics and US Generics.

They also make specialty APIs that include steroids, hormones, peptides and anti-
cancers manufactured at 14 international standard manufacturing facilities around the world.

Over 72% of Sun Pharma sales are from overseas markets. The US is its single largest market,
accounting for almost 60% of its turnover.

SUNPHARMA AT GLANCE:

Employees 30,000+

Turnover (year ended 31 March 2015) USD 4.5 billion

Markets Served 150+

Products 2000+

Manufacturing Facilities 48

Patents Granted 951

Market Share (India) 8.9%

Distributors & Sales Reps (India) 2,500+

Key brands 14
Approvals
FDA-USA, EMA-Europe, MHRA-UK, MCC-South Africa, TGA-Australia, ANVISA-Brazil, WHO-Geneva,
BfArM-Germany, KFDA-Korea and PMDA-Japan

SUNPHARMA FINANCIAL SNAPSHOT: BY ECONOMIC TIMES

By analysing Sunpharmaceutical Industries total revenue

and market share, it is ascertaining that its earning revival
is expected to continue in the coming years. Post-merger
the company has seen a lot of issues but somehow
manged to sustain in the market and gave valuable
products in the expected time frame. Also, battling pricing
pressures in the US and at home, Sun Pharmaceutical
Industries has projected a revenue growth of 8-10 per cent
in the year ahead which projects the company’s inherent
valuation.

This sustainable competitive force that the company exert

after many downfall, itself is commendable hence we are
choosing Sun pharma as our company for valuation.

The project help in identifying intrinsic facts, key issues,

ratio analysis, critical analysis and overall comparison of
company’s performance with its competitors. For this per
se we have chosen sun pharma’s financial statement 2017-
18.